866-997-4948(US-Canada Toll Free)

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 186 Pages

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016, provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
- The report reviews Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics and enlists all their major and minor projects
- The report assesses Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Overview 9
Therapeutics Development 10
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Stage of Development 10
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Therapy Area 11
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Indication 12
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Companies 17
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Universities/Institutes 30
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Therapeutics Assessment 32
Assessment by Monotherapy/Combination Products 32
Assessment by Mechanism of Action 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Companies Involved in Therapeutics Development 38
Abeome Corporation 38
Alnylam Pharmaceuticals, Inc. 39
AlphaMab Co., Ltd 40
AstraZeneca Plc 41
Aurigene Discovery Technologies Limited 42
Avacta Group Plc 43
BeiGene, Ltd. 44
Bristol-Myers Squibb Company 45
CBT Pharmaceuticals Inc 46
CytomX Therapeutics, Inc. 47
Eli Lilly and Company 48
F. Hoffmann-La Roche Ltd. 49
Genosco 51
ImmunoCellular Therapeutics, Ltd. 52
Immunocore Limited 53
IO Biotech ApS 54
Kadmon Corporation, LLC 55
Kymab Limited 56
MedImmune, LLC 57
Merck KGaA 59
Merus NV 60
Novartis AG 61
PsiOxus Therapeutics Limited 62
Regeneron Pharmaceuticals Inc 63
Shanghai Henlius Biotech Co., Ltd. 64
Sorrento Therapeutics, Inc. 65
Sutro Biopharma, Inc. 66
Theravectys SA 67
Tikcro Technologies, Ltd. 68
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drug Profiles 69
ALN-PDL - Drug Profile 69
Antibody to Inhibit PD-L1 for Oncology - Drug Profile 70
Antisense Oligonucleotide to Inhibit PD-L1 for Oncology - Drug Profile 71
atezolizumab - Drug Profile 72
avelumab - Drug Profile 86
AZD-1775 + durvalumab - Drug Profile 92
Biologic to Inhibit PD-L1 for Immunology - Drug Profile 93
BMS-936559 - Drug Profile 94
CA-170 - Drug Profile 96
CA-327 - Drug Profile 98
CBA-0710 - Drug Profile 99
CBT-502 - Drug Profile 100
Cellular Immunotherapy to Inhibit PD-L1 for Oncology - Drug Profile 101
CX-072 - Drug Profile 102
dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 103
durvalumab - Drug Profile 104
durvalumab + gefitinib - Drug Profile 115
durvalumab + IMCgp-100 + tremelimumab - Drug Profile 116
durvalumab + MEDI-0562 - Drug Profile 117
durvalumab + MEDI-0680 - Drug Profile 118
durvalumab + monalizumab - Drug Profile 119
durvalumab + oleclumab - Drug Profile 120
durvalumab + selumetinib sulfate - Drug Profile 121
durvalumab + tremelimumab - Drug Profile 122
FAZ-053 - Drug Profile 126
GNS-1480 - Drug Profile 127
HLX-10 - Drug Profile 128
HLX-20 - Drug Profile 129
HTI-1316 - Drug Profile 130
IO-103 - Drug Profile 131
KD-033 - Drug Profile 132
KN-035 - Drug Profile 133
KY-1003 - Drug Profile 134
LY-3300054 - Drug Profile 135
MCLA-145 - Drug Profile 136
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 137
Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 138
Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 139
Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 140
Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 141
Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors - Drug Profile 142
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 143
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 144
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 145
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 146
Monoclonal Antibody to Inhibit PDL-1 for Influenza - Drug Profile 147
Monoclonal Antibody to Inhibit PDL1 for Oncology - Drug Profile 148
Monoclonal Antibody to Target EGFR and to Inhibit PD-L1 for Oncology - Drug Profile 149
Oncolytic Viruses to Inhibit PDL1 for Solid Tumors - Drug Profile 150
Recombinant Proteins to Inhibit PD-L1 for Solid Tumor - Drug Profile 151
Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology - Drug Profile 152
SNPDL-01 - Drug Profile 153
STIA-1011 - Drug Profile 154
STIA-1012 - Drug Profile 155
STIA-1014 - Drug Profile 156
STIA-1015 - Drug Profile 157
Synthetic Peptide 1 to Inhibit PD-L1 for Oncology - Drug Profile 158
Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 159
Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 160
Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 161
WBP-3155 - Drug Profile 162
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Dormant Projects 163
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Discontinued Products 164
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Featured News & Press Releases 165
Appendix 181
Methodology 181
Coverage 181
Secondary Research 181
Primary Research 181
Expert Panel Validation 181
Contact Us 181
Disclaimer 182

List of Tables
Number of Products under Development for, H2 2016 14
Number of Products under Development by Therapy Area, H2 2016 15
Number of Products under Development by Indication, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Development by Companies, H2 2016 (Contd..3) 26
Products under Development by Companies, H2 2016 (Contd..4) 27
Products under Development by Companies, H2 2016 (Contd..5) 28
Products under Development by Companies, H2 2016 (Contd..6) 29
Products under Development by Companies, H2 2016 (Contd..7) 30
Products under Development by Companies, H2 2016 (Contd..8) 31
Products under Development by Companies, H2 2016 (Contd..9) 32
Products under Development by Companies, H2 2016 (Contd..10) 33
Number of Products under Investigation by Universities/Institutes, H2 2016 34
Products under Investigation by Universities/Institutes, H2 2016 35
Assessment by Monotherapy/Combination Products, H2 2016 36
Number of Products by Stage and Mechanism of Action, H2 2016 37
Number of Products by Stage and Route of Administration, H2 2016 39
Number of Products by Stage and Molecule Type, H2 2016 41
Pipeline by Abeome Corporation, H2 2016 42
Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 43
Pipeline by AlphaMab Co., Ltd, H2 2016 44
Pipeline by AstraZeneca Plc, H2 2016 45
Pipeline by Aurigene Discovery Technologies Limited, H2 2016 46
Pipeline by Avacta Group Plc, H2 2016 47
Pipeline by BeiGene, Ltd., H2 2016 48
Pipeline by Bristol-Myers Squibb Company, H2 2016 49
Pipeline by CBT Pharmaceuticals Inc, H2 2016 50
Pipeline by CytomX Therapeutics, Inc., H2 2016 51
Pipeline by Eli Lilly and Company, H2 2016 52
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 53
Pipeline by Genosco, H2 2016 55
Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016 56
Pipeline by Immunocore Limited, H2 2016 57
Pipeline by IO Biotech ApS, H2 2016 58
Pipeline by Kadmon Corporation, LLC, H2 2016 59
Pipeline by Kymab Limited, H2 2016 60
Pipeline by MedImmune, LLC, H2 2016 61
Pipeline by Merck KGaA, H2 2016 63
Pipeline by Merus NV, H2 2016 64
Pipeline by Novartis AG, H2 2016 65
Pipeline by PsiOxus Therapeutics Limited, H2 2016 66
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 67
Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 68
Pipeline by Sorrento Therapeutics, Inc., H2 2016 69
Pipeline by Sutro Biopharma, Inc., H2 2016 70
Pipeline by Theravectys SA, H2 2016 71
Pipeline by Tikcro Technologies, Ltd., H2 2016 72
Dormant Projects, H2 2016 167
Discontinued Products, H2 2016 168

List of Figures
Number of Products under Development for, H2 2016 14
Number of Products under Development by Therapy Area, H2 2016 15
Number of Products under Development by Top 10 Indication, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Assessment by Monotherapy/Combination Products, H2 2016 36
Number of Products by Stage and Mechanism of Actions, H2 2016 37
Number of Products by Routes of Administration, H2 2016 38
Number of Products by Stage and Routes of Administration, H2 2016 38
Number of Products by Molecule Types, H2 2016 40
Number of Products by Stage and Molecule Type, H2 2016 40

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *